Table 1.
Patients’ socio-demographics and disease characteristics
| Patients’ characteristics | Total | Female | Male | P-value | |||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | ||
| N (%) | 223 | (100) | 93 | (41.7) | 126 | (56.5) | – |
| Age [year]: | 0.14 | ||||||
| 18–30 | 80 | (37.0) | 36 | (40.0) | 44 | (34.9) | |
| 31–40 | 75 | (34.7) | 35 | (38.9) | 40 | (31.8) | |
| > 40 | 61 | (28.2) | 19 | (21.1) | 42 | (33.3) | |
| Age at onset of disease [years]: | < 0.001 | ||||||
| < 15 | 56 | (26.7) | 35 | (39.3) | 21 | (17.4) | |
| 15–25 | 90 | (42.9) | 37 | (41.6) | 53 | (43.8) | |
| > 25 | 64 | (30.5) | 17 | (19.1) | 47 | (38.8) | |
| Disease duration [year]: | 0.04 | ||||||
| < 6 | 53 | (25.5) | 20 | (23.0) | 33 | (27.3) | |
| 6–15 | 75 | (36.1) | 25 | (28.7) | 50 | (41.3) | |
| > 15 | 80 | (38.5) | 42 | (48.3) | 38 | (31.4) | |
| Disease severity (sa-SPI-s): | 0.77 | ||||||
| Mild (< 10) | 120 | (57.1) | 54 | (60.0) | 66 | (55.0) | |
| Moderate (10–20) | 55 | (26.2) | 22 | (24.4) | 33 | (27.5) | |
| Severe (> 20) | 35 | (16.7) | 14 | (15.6) | 21 | (17.5) | |
| Impact of psoriasis on daily life (sa-SPI-p): | 0.55 | ||||||
| < 4 | 64 | (30.2) | 26 | (28.3) | 38 | (31.7) | |
| 4–7 | 67 | (31.6) | 27 | (29.4) | 40 | (33.3) | |
| > 7 | 81 | (38.2) | 39 | (42.4) | 42 | (35.0) | |
| Previous/ongoing depression diagnosis | 37 | (17.1) | 12 | (12.9) | 25 | (20.2) | 0.16 |
| Previous/current medication for depression | 11 | (5.1) | 4 | (4.3) | 7 | (5.7) | 0.66 |
| Previous/ongoing anxiety diagnosis | 76 | (34.7) | 41 | (44.1) | 35 | (27.8) | 0.01 |
| Previous/current medication for anxiety | 14 | (6.5) | 5 | (5.5) | 9 | (7.1) | 0.63 |
| Education level: | < 0.001 | ||||||
| Below secondary | 35 | (16.1) | 10 | (10.8) | 25 | (20.2) | |
| Secondary | 51 | (23.5) | 12 | (12.9) | 39 | (31.5) | |
| Higher | 131 | (60.4) | 71 | (76.3) | 60 | (48.4) | |
| Marital status: | 0.003 | ||||||
| Married | 128 | (58.7) | 43 | (46.2) | 85 | (68.0) | |
| Single | 85 | (39.0) | 46 | (49.5) | 39 | (31.2) | |
| Divorced | 5 | (2.3) | 4 | (4.3) | 1 | (0.8) | |
| Country†: | 0.72 | ||||||
| Algeria | 64 | (31.2) | 32 | (38.1) | 32 | (26.5) | |
| Iraq | 52 | (25.4) | 20 | (23.8) | 32 | (26.5) | |
| Egypt | 25 | (12.2) | 9 | (10.7) | 16 | (13.2) | |
| Syria | 16 | (7.8) | 4 | (4.8) | 12 | (9.9) | |
| Tunisia | 15 | (7.3) | 6 | (7.1) | 9 | (7.4) | |
| Morocco | 14 | (6.8) | 6 | (7.1) | 8 | (6.6) | |
| Jordan | 10 | (4.9) | 4 | (4.8) | 6 | (5.0) | |
| Other Arabic country | 9 | (4.4) | 3 | (3.6) | 6 | (5.0) | |
Results are n (%). sa-SPI-s – self-assessed Simplified Psoriasis Index-severity scale, sa-SPI-p –self-assessed Simplified Psoriasis Index-psychosocial impact.
†
Country was missingforl8 patients